Tiffany Lam

This study shows that JAK1/2 inhibition with ruxolitinib improves survival and body weight in lung cancer models by increasing food intake and restoring metabolic function.

Congenital T cell activation in CTLA4-deficient patients impairs transitional to follicular B cell maturation and can be rescued by CTLA4 replacement therapy in vivo.